BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 36059510)

  • 1. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
    Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
    Front Immunol; 2022; 13():954440. PubMed ID: 36059510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
    Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
    Front Immunol; 2022; 13():933241. PubMed ID: 36211378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis-Related 4-Gene Risk Model for Predicting Immunotherapy Drug Response and Prognosis of Kidney Renal Clear Cell Carcinoma.
    Guo JS; Ding H; Wu PY; Xin ZY; Li JX; Jo HS; Ma ZH
    Chin Med Sci J; 2023 Sep; 38(3):191-205. PubMed ID: 37503721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and potential immune involvement of cuproptosis in kidney renal clear cell carcinoma.
    Liu H
    Cancer Genet; 2023 Jun; 274-275():21-25. PubMed ID: 36963335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
    Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
    Yao Y; Chen H; Lou M; Chen T
    Front Genet; 2023; 14():1071694. PubMed ID: 36755576
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular Subtyping Based on Cuproptosis-Related Genes and Characterization of Tumor Microenvironment Infiltration in Kidney Renal Clear Cell Carcinoma.
    Ji ZH; Ren WZ; Wang HQ; Gao W; Yuan B
    Front Oncol; 2022; 12():919083. PubMed ID: 35875087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cuproptosis-Related Ferroptosis genes for Predicting Prognosis in kidney renal clear cell carcinoma.
    Luo G; Wang L; Zheng Z; Gao B; Lei C
    Eur J Med Res; 2023 May; 28(1):176. PubMed ID: 37189176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular subtypes based on cuproptosis regulators and immune infiltration in kidney renal clear cell carcinoma.
    Liu A; Li Y; Shen L; Li N; Zhao Y; Shen L; Li Z
    Front Genet; 2022; 13():983445. PubMed ID: 36338990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.
    Yuan H; Qin X; Wang J; Yang Q; Fan Y; Xu D
    Front Immunol; 2022; 13():971142. PubMed ID: 36131921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.
    Li D; Wu X; Song W; Cheng C; Hao L; Zhang W
    Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analyses of cuproptosis-related gene CDKN2A on prognosis and immunologic therapy in human tumors.
    Zhang D; Wang T; Zhou Y; Zhang X
    Medicine (Baltimore); 2023 Apr; 102(14):e33468. PubMed ID: 37026918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma.
    Wang B; Song Q; Wei Y; Wu X; Han T; Bu H; Tang S; Qian J; Shao P
    Front Immunol; 2022; 13():948042. PubMed ID: 36275737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Survival Risk and Immune-Related Characteristics of Kidney Renal Clear Cell Carcinoma.
    Wu X; Liang Y; Chen X; Long X; Xu W; Liu L; Wang B; Zou X
    J Immunol Res; 2022; 2022():6149369. PubMed ID: 35832648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value and immunological characteristics of a novel cuproptosis-related long noncoding RNAs risk signature in kidney renal clear cell carcinoma.
    Hong P; Huang W; Du H; Hu D; Cao Q; Wang Y; Zhang H; Tong S; Li Z; Tong M
    Front Genet; 2022; 13():1009555. PubMed ID: 36406128
    [No Abstract]   [Full Text] [Related]  

  • 17. Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma.
    Xia QD; Li B; Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhang SH; Zhong XY; Zeng N; Ma SY; He HD; Zhang YC; Guan W; Li H; Wang SG
    Front Oncol; 2023; 13():1096341. PubMed ID: 37035135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of M7G-related lncRNAs in kidney renal clear cell carcinoma and their putative diagnostic and prognostic role.
    Zhong S; Chen S; Lin H; Luo Y; He J
    BMC Urol; 2023 Nov; 23(1):186. PubMed ID: 37968670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.